A low-cost HIV prevention jab, lenacapavir, will be available in 120 lower-income countries starting in 2027, priced at $40 per year. This generic version aims to improve access amid cuts to global health budgets. The jab, approved by the EMA and FDA, is a significant medical breakthrough that could impact the global HIV epidemic affecting 40.8 million people. Initial costs include two oral tablets for immediate protection. Gilead, the drug's manufacturer, plans to provide lenacapavir to two million people in lower-income countries, with support from organizations like Unitaid and CHAI. Teljes cikk (Euronews.com)